Suppr超能文献

眼肌型重症肌无力

Ocular myasthenia gravis.

作者信息

Elrod Rachael D, Weinberg David A

机构信息

Department of Neuro-Ophthalmology and Ophthalmic Plastic Surgery, Division of Ophthalmology, University of Vermont College of Medicine, Burlington, VT 05401, USA.

出版信息

Ophthalmol Clin North Am. 2004 Sep;17(3):275-309; v. doi: 10.1016/j.ohc.2004.05.014.

Abstract

Myasthenia gravis may be limited solely to the eyes (ocular myasthenia) or may have systemic manifestations (generalized myasthenia). Most patients display blepharoptosis or ophthalmoparesis, resulting in diplopia, but the ocular motility disorder may take many forms. The diagnosis is often elucidated by variable muscle weakness with fatigability noted in the history and on examination. The ice test has supplanted the need for the edrophonium (Tensilon) test in many cases of ocular myasthenia. Therapy may be challenging, because many ocular myasthenics do not achieve significant clinical improvement with acetylcholinesterase inhibitors alone. Immunomodulatory treatment,such as systemic corticosteroids, is frequently effective, and emerging data suggest that this type of therapy may reduce the likelihood of ocular myasthenia becoming generalized.

摘要

重症肌无力可能仅局限于眼部(眼肌型重症肌无力),也可能有全身表现(全身型重症肌无力)。大多数患者表现为上睑下垂或眼球运动障碍,导致复视,但眼球运动障碍可能有多种形式。根据病史和检查中发现的可变肌无力伴疲劳现象,通常可明确诊断。在许多眼肌型重症肌无力病例中,冰试验已取代了依酚氯铵(腾喜龙)试验的必要性。治疗可能具有挑战性,因为许多眼肌型重症肌无力患者仅使用乙酰胆碱酯酶抑制剂无法取得显著的临床改善。免疫调节治疗,如全身使用皮质类固醇,通常有效,新出现的数据表明,这类治疗可能会降低眼肌型重症肌无力发展为全身型的可能性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验